Patent 11976096 was granted and assigned to Ginkgo Bioworks on May, 2024 by the United States Patent and Trademark Office.
The present disclosure provides recombinant AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the recombinant AAV capsid proteins. The disclosure also provides methods of administering the virus vectors and vims capsids of the disclosure to a cell or to a subject in vivo.